Ipamorelin vs sermorelin

One was an approved medicine, one never got past phase 2 — does that difference mean anything for what they do?

No head-to-head trial — cross-trial comparison
In one paragraphSermorelin is a GHRH fragment that was approved decades ago as a diagnostic and paediatric growth-hormone medicine, later withdrawn for commercial rather than safety reasons, and is now compounded on prescription in the United States. Ipamorelin is a ghrelin-receptor agonist that was never approved anywhere and whose only randomised trial was negative. Sermorelin therefore has approval-grade evidence that it raises growth hormone; neither has evidence that doing so changes anything in a healthy adult.

Side by side

C IpamorelinC Sermorelin
LYO overall gradeCC
MechanismGhrelin / GH-secretagogue receptor agonistGHRH(1–29) — the active fragment of natural GHRH
Ever approvedNoYes — as Geref, later withdrawn commercially
Strongest evidenceAcute GH release; 1 negative randomised outcome trialApproval-grade GH/IGF-1 response data
Randomised outcome trial1 — post-operative ileus, primary endpoint missedNone in healthy adults
Body-composition evidence in adultsNoneSmall, mostly open-label studies
US legal positionUnapproved research chemicalCompounded on prescription
Sport (WADA)Prohibited at all times (S2)Prohibited at all times (S2)
Verdict

Sermorelin has the stronger regulatory pedigree and the clearer legal position in the US. Neither has a controlled trial supporting the body-composition and recovery claims they are actually sold for.

Different receptors, same marker

Sermorelin is simply the first 29 amino acids of human GHRH — the part that does the work. It acts on the GHRH receptor and preserves the body's own pulsatile release, which is the pharmacological argument for using a secretagogue instead of injecting growth hormone directly. Ipamorelin comes at the same marker from the ghrelin receptor, and is notable for being selective: unlike the older GHRPs it produces little cortisol or prolactin rise.

Both raise growth hormone. That is where the shared evidence ends.

Why the approval matters — and why it matters less than it looks

Sermorelin's approval was real, and it means the GH response was documented to a regulatory standard. But it was approved as a diagnostic agent and for growth-hormone deficiency in children, not for adults wanting muscle or better sleep. It was withdrawn from the market for commercial reasons, which is why it can still be compounded in the US: it was never placed on the FDA's list of substances presenting significant safety risks.

So the approval tells you the molecule does what it says to a hormone. It tells you nothing about the uses it is now sold for, which were never the subject of a trial.

The one real outcome trial

Between the two, only ipamorelin has been taken into a randomised trial with a clinical endpoint: 117 patients recovering from bowel surgery, testing whether a ghrelin agonist would restore gut motility faster. Median time to a tolerated solid meal was 25.3 hours against 32.6 on placebo, p=0.15, with no difference on secondary endpoints. It was well tolerated over seven days of intravenous dosing. Development stopped.

A negative trial is more informative than no trial. It is the only place either of these compounds has been asked to produce a result a patient would notice.

Questions people actually ask

Is sermorelin safer because it was once approved?
Its short-term safety was characterised to a regulatory standard, which ipamorelin's never was. That is not the same as long-term safety at the doses and durations used outside medicine, which has not been studied for either.
Which is better for muscle?
Neither has a controlled human trial for muscle or body composition. Any ranking you read is extrapolation from hormone levels.
Why is sermorelin available on prescription in the US but ipamorelin is not?
Sermorelin was an approved drug withdrawn for commercial reasons and was not placed on the FDA's safety-risk list, so pharmacies may compound it. Ipamorelin has no such history and is sold as an unapproved research chemical.

References

  1. 1
  2. 2
  3. 3